Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: July 7, 2026
Reporting Period: Event date July 7, 2026
Business Focus: Developer of noninvasive lung cancer diagnostics, specifically the CyPath® Lung product.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain audited financial statements, revenue figures, profit data, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes
- Sales Growth: The company reported continued acceleration in commercial sales for its CyPath® Lung diagnostic.
- Year-Over-Year Performance: Sales growth exceeded 200% compared to the prior year.
Guidance, Outlook, and Management Commentary
Management Commentary: The President and CEO, Maria Zannes, signed the report confirming the announcement of sales acceleration. The company issued a press release (Exhibit 99.1) detailing the commercial progress of CyPath® Lung.
Outlook: The filing indicates positive momentum in commercial adoption but does not provide specific forward-looking financial guidance or numerical targets.
Risks and Contingencies: No specific risks or contingencies are detailed within the text of this 8-K filing.
Investor Verification Checklist
- Verify the specific revenue figures and customer adoption rates referenced in the attached Press Release (Exhibit 99.1).
- Confirm the definition of "commercial sales" used to calculate the 200% year-over-year growth metric.
- Review the company's most recent 10-Q or 10-K for baseline financial health, cash runway, and debt obligations not included in this 8-K.
- Assess the competitive landscape for noninvasive lung cancer diagnostics to contextualize the sales acceleration.